Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024.
2024年8月1日维州阿什本(GLOBE NEWSWIRE)-- Quoin Pharmaceuticals Ltd.(纳斯达克:QNRX)(以下简称"公司"或"Quoin"),一家专注于罕见和孤儿病的临床专业药品公司,今天宣布该公司计划于2024年8月8日星期四市场开盘前发布2024年第二季度财务业绩报告。
The announcement will provide an operational update regarding the company's achievements during the quarter and will detail financial highlights.
该公告将提供有关公司在该季度取得成就的运营更新,并详细说明财务亮点。
About Quoin Pharmaceuticals Ltd.
关于Quoin Pharmaceuticals Ltd.公司:Quoin Pharmaceuticals Ltd.是一家专注于开发和商业化治疗罕见和孤儿疾病的治疗产品的临床专业药品公司。我们致力于满足患者、家庭、社区和护理团队的未满足的医疗需求。Quoin的创新管道包括四种正在研发的产品,具有共同的潜力,以针对广泛的罕见和孤儿适应症,包括内瑟顿综合征、剥脱性皮肤综合征、掌跖角化症、硬皮病、表皮松解性水疱病和其他疾病。欲获取更多信息,请访问:Quoin Pharmaceuticals Ltd.网站或LinkedIn更新。
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: or LinkedIn for updates.
公司提醒,本新闻稿中不是历史事实描述的陈述均属于根据1995年《私人证券诉讼改革法》的前瞻性陈述。前瞻性陈述可能通过使用涉及未来事件或情况的词语,如"预期"、"意图"、"计划"、"预测"、"相信"和"将"等等进行识别。除了历史事实的陈述外,反映公司对未来的期望、假设、投影、信念或意见的所有陈述均为前瞻性陈述。因为这些陈述存在风险和不确定性,实际结果可能与这些前瞻性陈述所表达的结果存在实质性的差异。这些前瞻性陈述基于公司目前的预期并涉及可能永远无法实现或可能被证明不正确的假设。实际结果和事件的时间可能与这些前瞻性陈述所预期的结果和事件的时间存在实质性的差异。有关可能导致实际结果与本新闻稿中所包含信息不符的因素的更多信息,请参阅该公司提交给SEC的截至2023年12月31日的10-K表和该公司随后提交给SEC的表格10-Q和8-K。该公司不承担更新这些陈述以反映其所做陈述之后发生的事件或存在的情况的义务,但法律可能要求该公司这样做。
Cautionary Note Regarding Forward Looking Statements
关于前瞻性声明的警告
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. For additional information concerning factors that could cause actual results to differ materially from the information contained in this press release, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2023 that the Company filed with the SEC and the Company's subsequent filings with the SEC on Forms 10-Q and 8-K. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
公司注意到,本新闻稿中非历史事实描述的陈述属于《1995年《私人证券诉讼改革法》》规定的前瞻性陈述。前瞻性陈述可能是使用涉及未来事件或情况的词语,如“预计”,“打算”,“计划”,“预测”,“相信”和“将要”等。除历史事实陈述外,反映公司对未来的期望,假设,投射,信念或意见的所有陈述,均属于前瞻性陈述。由于这些陈述存在风险和不确定性,实际结果可能与此类前瞻性陈述所表达或暗示的结果有所不同。这些前瞻性陈述基于公司当前的期望,并涉及可能永远无法实现或可能被证明不正确的假设。实际结果和事件的时间可能与此类前瞻性陈述所预计的有所不同。有关可能导致实际结果与本新闻稿所包含信息有所不同的因素的附加信息,请查阅公司在2023年12月31日结束的10-K表格和公司在SEC提交的之后关于10-Q和8-K表格的提交。除法律另有规定外,公司无义务更新此类陈述以反映发生或存在于其发布之后的事件或情况。
For further information, contact:
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
如需更多信息,请联系:
投资者关系
PCG 咨询
杰夫·拉姆森
jramson@pcgadvisory.com
(646) 863-6341